gets stuck, and scar tissue proliferates uncontrollably in a tissue or organ, to the point where it malfunctions. Fibrosis is implicated in a number of diseases, common and uncommon, but Promedior is focusing on some of the rarest conditions resulting from a scarring process run amok.
Promedior recently completed a Phase Ib clinical study of its lead drug candidate, PRM-151, for idiopathic pulmonary fibrosis, a form of severe lung scarring that can only be treated with a lung transplant; the company expects to publish the results in 2013. Bruhn says Promedior also plans to start a trial of the drug in myelofibrosis, scarring in the bone marrow that leads to severe anemia, during the first half of next year.
Promedior is well set financially, she says, having raised $24.5 million in equity funding this year. In total Promedior has raised $65 million, and its investors include Shire, her former employer. Bruhn says that, with the move completed, she is eager to move forward with what she considers Promedior’s “disruptive innovation.” Almost as disruptive as being a woman at the top.
Pages: Page 1, Page 2, Page 3
Author: Catherine Arnst
Catherine Arnst is an award- winning writer and editor specializing in science and medicine. Catherine was Senior Writer for medicine at BusinessWeek for 13 years, where she wrote numerous cover stories and wrote extensively for the magazine’s website, including contributing to two blogs. She followed a broad range of issues affecting medicine and health and held primary responsibility for covering the battle in Washington over health care reform. Catherine has also written for the Boston Globe, U.S. News & World Report and The Daily Beast, and was Director of Content Development for the health practice at Edelman Public Relations for two years. Prior to joining BusinessWeek she was the London-based European Science Correspondent for Reuters News Service. She won the 2004 Business Journalist of the Year award from London’s World Leadership Forum, and in 2003 was the first recipient of the ACE Reporter Award from the European School of Oncology for her five-year body of work on cancer. She holds a bachelor’s degree in journalism from Boston University.
View all posts by Catherine Arnst
